News & Events 2022
2 August 2022
A seminar titled 'An Effort to Build a Cervical Cancer Free Bangladesh' and the unveiling of Incepta's new vaccine Papillovax were held at the capital's Pan Pacific Sonargaon Hotel on Tuesday, August 2.
The seminar discussed the need for HPV vaccine (human papillomavirus) in the country and how regular screening and introduction of HPV vaccine (human papillomavirus) Papillovax can contribute to achieving a cervical cancer free country.
Dr. expert doctor in the seminar. TA Chowdhury and National Professor Shahla Khatun delivered speeches as chief guests. The seminar was presided over by the president of OGSB (Obstetrical and Gynecological Society of Bangladesh) Professor Dr. Ferdowsi Begum. Professor Dr. The seminar started with welcome address by Gulshan Ara.
Former Chairman of Gynecology Oncology Department of Bangabandhu Sheikh Mujib Medical University Prof. Dr. Sabera Khatun and Manager (MSD) of Incepta Pharmaceuticals Farhana Laiju presented on the subject in the seminar. Scientific Secretary of OGSB, Professor Sheikh Jinnat Ara Nasreen moderated the excellent question and answer session.
Incepta Pharmaceuticals Ltd. expressed thanks on behalf of Incepta at the seminar. Executive Director Dr. EH Arefin Ahmed. Finally, Incepta officially unveiled PapilloVax, heralding a new era in cervical cancer prevention.
To eliminate cervical cancer, the HPV vaccine is the first step. There was a huge gap in this vaccine in Bangladesh for the past few years. Incepta Vaccine Ltd., the country's first vaccine manufacturing company, has come forward to fill this gap. and started marketing the country's first cervical cancer vaccine, Papillovax. It is a matter of pride for the country, which will pave the way to eradicate cervical cancer from the country.
18 July 2022
Incepta Vaccine Limited launched its cervical cancer vaccine "Papilovax" for the first time in Bangladesh as a local company.
Papilovax protects women against cervical cancer by countering the HPV virus responsible for the disease.
Women 9-45 years in age should receive three doses of Papilovax. The second dose should be taken one month after the first dose and the third dose should be received six months after that.
Completing the full course of this vaccine will reduce the risk of developing cervical cancer throughout a woman's lifetime.
Cervical cancer is the second deadliest among different types of cancers that cause female deaths in Bangladesh. Every year more than 10,000 women die of cervical cancer in the country and more than five crore women are at risk.
Papilovax is marketed in modern pre-filled syringes. The full dose in pre-filled syringes is manufactured in an aseptic environment and marketed at controlled temperatures in fully sterile packaging.
1 January
Incepta Proudly Introduces Tolosa 80
Tocilizumab 80 mg
First ever global biosimilar of Tocilizumab
Emergency Use Authorization
To control the cytokine storm in COVID-19 patients.
